Mefro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 27-06-2024
- Paid Up Capital ₹ 0.50 M
as on 27-06-2024
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.24 Cr
as on 27-06-2024
- Satisfied Charges ₹ 1.50 Cr
as on 27-06-2024
- Revenue %
(FY 2022)
- Ebitda
- Net Worth
- Total Assets %
(FY 2022)
About Mefro Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.24 Cr. The company has closed loans amounting to ₹1.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Gamini Chopra and Rajesh Chopra serve as directors at the Company.
- CIN/LLPIN
U24232PB1995PTC016505
- Company No.
016505
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationPunjab, Punjab
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mefro Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gamini Chopra  | Director | 15-Feb-2001 | Current |
| Rajesh Chopra | Director | 23-Oct-2000 | Current |
Financial Performance of Mefro Pharmaceuticals.
Mefro Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Mefro Pharmaceuticals?
Unlock access to Mefro Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Horizon Formulations Private LimitedActive 19 years 1 month
Gamini Chopra and Rajesh Chopra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Jul 2020 | ₹8.90 M | Open |
Icici Bank Limited Creation Date: 01 Sep 2014 | ₹1.00 Cr | Open |
State Bank Of India Creation Date: 15 Feb 2005 | ₹3.00 M | Open |
How Many Employees Work at Mefro Pharmaceuticals?
Unlock and access historical data on people associated with Mefro Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mefro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mefro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
